AARTIDRUGS.NSE

Aarti Drugs Ltd.

In this briefing: Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong JK Lakshmi Cement Limited - Lower Realisation Impacted Performance; Retain BUY Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 1. Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth Maturing Gurugram Micro-Markets: Signature Global’s portfolio remains heavily concentrated in the micro-markets of Gurugram. Housing demand in Gurugram is transitioning from a fast, hype-driven phase to a more stable, end-user-led market. As a result, the company’s annual pre-sales are likely to normalise at around ~Rs 10,000 Cr, with price growth moderating to gradual high single digits. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong JK Lakshmi Cement Limited - Lower Realisation Impacted Performance; Retain BUY Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 India: Trade Agreements to Attract Foreign Investment 1. Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong Demand recovery combined with strong value strategy: The company is witnessing a clear improvement in guest counts from December onwards, with January trends continuing to remain positive. The Rs 99 value platform has now been rolled out across the West and select South markets without any adverse impact on gross margins, underscoring effective cost control. Management’s focus remains firmly on driving higher footfalls rather than only increasing ticket size, which is an appropriate strategy in a soft demand environment. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 India: Trade Agreements to Attract Foreign Investment India: EU FTA, US Tariff Reductions Dovetail with Budget's Manufacturing Focus Aequitas: Turtlemint Fintech Solutions Limited Pre-IPO Tearsheet 1. Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Revenue Performance: Trent posted a 16% YoY revenue growth in Q3FY26, with sales reaching Rs 5,259 Cr. However, the early festive season and the transition to the revised GST structure impacted QoQ comparability. In the near term, consumers showed a preference for higher-value purchases that benefited more from GST reductions, though demand for lower-ticket discretionary categories is expected to normalise over the medium term. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

In this briefing: Primer: HeXun Biosciences (6986 TT) - Nov 2025 Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. Primer: HeXun Biosciences (6986 TT) - Nov 2025 HeXun Biosciences operates a unique and synergistic dual-strategy business model, leveraging stable cash flow from its Contract Development and Manufacturing Organization (CDMO) services to fund its in-house development of high-potential stem cell-based new drugs. The company is strategically positioned in the high-growth regenerative medicine and biologics markets, with a focus on mesenchymal stem cells (MSCs) for cardiovascular diseases, a leading cause of death globally. Recent financial performance demonstrates exceptional growth, with revenue increasing by 119.36% and net income by 339.62% in the most recent fiscal year, transitioning the company from a loss-making entity to a profitable one with strong margin expansion.